Abstract： Objective： To analyze the mechanism of Erchen Decoction in the treatment of liver cancer using network pharmacology and molecular docking technology. Methods： Active ingredients of Erchen Decoction were screened using the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform （TCMSP）. Potential targets of these active ingredients were retrieved from the Swiss Target Prediction database. Liver cancer- related targets were collected from the GeneCards，OMIM，and DrugBank databases. Venny 2.1.0 was used to identify overlapping targets between the active ingredients and liver cancer. A protein-protein interaction （PPI） network of the overlapping targets was constructed using the STRING database， and core targets were identified using Cytoscape 3.10.2. A "herb-active ingredient-target" network was also established using Cytoscape 3.10.2. Gene Ontology （GO） functional enrichment and Kyoto Encyclopedia of Genes and Genomes （KEGG） pathway enrichment analyses were performed on the core targets. Molecular docking of key active ingredients and core targets was conducted using AutoDockTools 1.5.7. Results： A total of 130 active ingredients and 966 potential targets were identified from Erchen Decoction. Screening yielded 1 020 liver cancer-related targets. There were 225 overlapping targets between the active ingredients and the disease，of which 53 were identified as core targets. The main active ingredients of Erchen Decoction included quercetin-3，3′-dimethyl ether， quercetin， baicalein， cerevisterol， 5， 7-dihydroxy-2-（3- hydroxy-4-methoxyphenyl）chroman-4-one （R-hesperetin）， and 6-methylgingediol diacetate. The main targets are signal transducer and activator of transcription 3 （STAT3）， sarcoma virus protein （SRC）， estrogen receptor 1 （ESR1）， AKT serine/threonine kinase 1 （AKT1）， phosphoinositol 3-kinase regulatory subunit 1 （PIK3R1）， epidermal growth factor receptor （EGFR）， and signal transducer and activator of transcription 1 （STAT1） . GO enrichment analysis indicated that the core targets were primarily involved in biological processes such as chromatin remodeling and negative regulation of apoptosis. KEGG enrichment analysis showed that the core targets were mainly associated with pathways in cancer and EGFR tyrosine kinase inhibitor resistance. Molecular docking results demonstrated stable binding between the key targets and the main active ingredients of Erchen Decoction. Conclusion： Network pharmacology analysis results indicate that Erchen Decoction may have potential therapeutic effects against liver cancer， likely through active ingredients such as quercetin-3， 3′-dimethyl ether， quercetin， baicalein， cerevisterol， R-hesperetin， and 6-methylgingediol diacetate acting on targets including STAT3， SRC， ESR1，AKT1，PIK3R1，EGFR，and STAT1 to regulate multiple pathways.